Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06085261
Other study ID # 2021-I2M-1-409
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date November 2023
Est. completion date December 2024

Study information

Verified date October 2023
Source China-Japan Friendship Hospital
Contact Ting Yang, MD
Phone 84206272
Email zryyyangting@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease(COPD) patients could benefit from pulmonary rehabilitation(PR) in better managing of the disease and its symptoms and in avoiding future relapses and hospitalizations. However, due to a large number of drop outs from PR, lack of professionals, and the (Corona Virus Disease 2019) COVID-19 epidemic, the PR has been underutilized, leading to a need for investigation of updated forms. The study aims to investigate the effects of a home-based PR program using minimal accessories, facilitated with wearable activity trackers and smartphones.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 360
Est. completion date December 2024
Est. primary completion date August 2024
Accepts healthy volunteers No
Gender All
Age group 40 Years to 75 Years
Eligibility Participants with a clinical diagnosis of and meeting the following criteria are eligible: 1. Diagnosis of COPD of Global Initiative for Chronic Obstructive Lung Disease (GOLD) II-IV and without acute exacerbation within the last 2 weeks. 2. Motivated for participating in the project (and acceptance of randomization) 3. Sufficient mobility to attend PR Exclusion Criteria: 1. Certain comorbidities (e.g. unstable coronary complications) 2. Severe cognitive disabilities (e.g. dementia) 3. Inability to cope with the program because of severe hearing or visual disorder.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
home-based telerehabilitation group
Participants will download the web application in their smartphones in the hospital's outpatient clinic and learn to use the sports wristwatch. Remotely supervised telerehabilitation at home will be conducted for 8 weeks, comprising lower limb aerobic training, individualized strength training and respiratory training exercises. The initial aerobic exercise prescription for walking will be set at 80% of the speed walked during a 6-minute walk test (6MWT) and progressed each 4-week according to patient assessments. Resistance training for the arms and legs will utilize elastic bands, while respiratory training will utilize portable breathing trainer. During each training session, participants will be asked to follow the videos in the web application, wearing the sports wristwatch recording their exercise intensity. At the end of every training session, training data could be uploaded to the web platform automatically, which will be checked by staff in hospital.
center-based traditional rehabilitation group
Participants will undertake an aerobic, strength and respiratory training program of similar intensity and duration to the home-based program, at their site of recruitment. The initial aerobic exercise prescription for cycling will be set at 60% of the peak oxygen uptake (VO2) on a cardiopulmonary exercise test (CPET). Resistance training and respiratory training are similar to the telerehabilitation group.

Locations

Country Name City State
China China-Japan Friendship hospital Beijing

Sponsors (1)

Lead Sponsor Collaborator
China-Japan Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6-minute walk distance (6MWD) 6-minute walk distance 8 weeks; 20 weeks
Secondary pulmonary function forced expiratory volume in 1 second (FEV1) [velocity] 8 weeks; 20 weeks
Secondary pulmonary function ratio between FEV1 and forced vital capacity (FEV1/FVC) [velocity] 8 weeks; 20 weeks
Secondary pulmonary function forced expiratory flow between 25 and 75% of forced vital capacity (FEF25-75%) [velocity] 8 weeks; 20 weeks
Secondary pulmonary function inspiratory capacity (IC) [velocity] 8 weeks; 20 weeks
Secondary pulmonary function residual volume (RV) [velocity] 8 weeks; 20 weeks
Secondary pulmonary function total lung capacity (TLC) [velocity] 8 weeks; 20 weeks
Secondary pulmonary function diffusing capacity of the lung for carbon monoxide (DLCO) [velocity] 8 weeks; 20 weeks
Secondary Respiratory muscle strength maximum inspiratory pressure(MIP), maximum expiratory pressure(MEP) 8 weeks; 20 weeks
Secondary Short Physical Performance Battery(SPPB) Test for health-related physical performance 8 weeks; 20 weeks
Secondary modified British medical research council(mMRC) It is a self-reported symptom questionnaire ranging from 0-4 score, higher scores mean a worse outcome. 8 weeks; 20 weeks
Secondary COPD assessment test(CAT) It is a self-reported quality of life questionnaire ranging from 0-10 score, higher scores mean a worse outcome. 8 weeks; 20 weeks
Secondary St. George's Respiratory Questionnaire (SGRQ) It is a self-reported symptom questionnaire ranging from 0-100 score, higher scores mean a worse outcome. 8 weeks; 20 weeks
Secondary Hospital Anxiety and Depression Scale(HADS) It is a self-reported psychological status questionnaire ranging from 0-42 score, higher scores mean a worse outcome. 8 weeks; 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy